A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
J Virol. 2021 Feb 23;95(10):e01819-20. doi: 10.1128/JVI.01819-20. Online ahead of print.
J Virol. 2021.
PMID: 33622961
Free PMC article.